TY - JOUR
T1 - The epidermal growth factor receptor (EGRF) in lung cancer
AU - Carcereny, Enric
AU - Morán, Teresa
AU - Capdevila, Laia
AU - Cros, Sara
AU - Vilà, Laia
AU - de Los Llanos Gil, Maria
AU - Remón, Jordi
AU - Rosell, Rafael
PY - 2015/2/24
Y1 - 2015/2/24
N2 - In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer.
AB - In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer.
KW - Lung cancer
KW - Epidermal growth factor receptor
KW - EGFR
KW - Tyrosine kinase inhibitors
KW - TKI
UR - https://europepmc.org/articles/PMC4366432
U2 - 10.1186/s40247-015-0013-z
DO - 10.1186/s40247-015-0013-z
M3 - Review article
SN - 2213-0802
VL - 3
JO - Translational respiratory medicine
JF - Translational respiratory medicine
IS - 1
M1 - 1
ER -
